#WCLC25: AstraZeneca’s Tagrisso combo extends survival by 10 months in EGFR-mutant lung cancer

The combination of AstraZeneca’s Tagrisso and chemotherapy cut the risk of death by 23% compared to Tagrisso alone for patients with advanced EGFR-mutant lung cancer. In the FLAURA2 study's key overall survival endpoint, patients who ...